ReviewBiological trace element research2026
Silver Nanoparticles (AgNPs) as a Double-Edged Sword: Synthesis, Factors Affecting, Mechanisms of Toxicity and Anticancer Potentials-An Updated Review till March 2025.
Review in Biological trace element research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Integrating silver nanomaterials in wound healing: from physicochemical properties to clinical translation.Journal of nanobiotechnology · 2026Review
- Review
- Contact-Dependent Antibacterial Performance of Silver Nanoparticles Encapsulated in Collagen-Based Gels.Journal of functional biomaterials · 2026Article
- Silver Nanoparticles as Anticancer Agents: Mechanisms Insight, Current Studies, and Limitations.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Equal nano-characteristics, unequal harm: the chemical composition of noble metal nanoparticles as the main factor of cytotoxicity.Frontiers in toxicology · 2026Article
- HarnessingInternational journal of nanomedicine · 2026Article
- Phytogenic Silver Nanoparticles Derived fromBioengineering (Basel, Switzerland) · 2025Article
- Nanoparticles Based Therapeutic Approaches in Oncogenic Viral Infections: A Review.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Silver nanoparticles (Ag-NPs) are widely utilized in cosmetics, healthcare, and antimicrobial products due to their potent antimicrobial and anticancer properties. However, their increasing use raises concerns about cytotoxic effects on human health and the environment. Ag-NPs interact with biological systems in a size-, dose-, and time-dependent manner, with particles smaller than 10 nm often exhibiting heightened toxicity. In vivo studies show their ability to cross the blood-brain barrier and accumulate in organs such as the liver, spleen, and brain. This review critically evaluates the cytotoxic mechanisms and anticancer therapeutic potential of Ag-NPs, presenting them as a double-edged sword. A comprehensive literature search was conducted on the PubMed, Scopus, Web of Science, etc. database for the period 2005-2025 using keywords including "Silver Nanoparticles AND anticancer," "tumor," and "cytotoxicity." The search yielded 1100 articles related to anticancer activity, 2879 on cytotoxicity, 460 on green-synthesized Ag-NPs tested for anticancer effects, and 3418 on green synthesis of AgNPs alone. The review discusses how physicochemical properties-such as size, shape, and surface chemistry-influence cytotoxicity through mechanisms like oxidative stress, mitochondrial damage, and DNA disruption. It also highlights recent advancements in Ag-NP synthesis and biomedical applications, underscoring the importance of balancing their therapeutic benefits against potential health risks.
Indexed as
Identifiers
40512370What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.